Pozen says FDA rejects two forms of its lead drug, shares fall

(Reuters) - Pozen Inc said two versions of its experimental heart drug were rejected for the second time by the U.S. Food and Drug Administration, which cited deficiencies in the manufacturing plant of a supplier of an active ingredient.

via Reuters: Health News Read More Here..